Suppr超能文献

在健康的日本女性中,两克乳果糖的益生元效应:一项随机、双盲、安慰剂对照交叉试验。

Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial.

机构信息

Food Ingredients & Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa 252-8583, Japan.

R&D Management Department, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama, Kanagawa 252-8583, Japan.

出版信息

Benef Microbes. 2019 Jul 10;10(6):629-639. doi: 10.3920/BM2018.0174. Epub 2019 May 27.

Abstract

Sixty healthy Japanese women with a defaecation frequency of 2-4 times/week participated in this randomised, double-blind crossover trial. Participants received 2 g/day lactulose for 2 weeks and placebo in a random order, separated by a washout period of 3 weeks. Eight participants were excluded who did not satisfy the conditions, and therefore data from 52 were analysed. The primary outcome was defaecation frequency and the secondary outcomes were the number of defaecation days, faecal consistency, faecal volume, and the number and percentage of in faeces. The defaecation frequency (times/week) was significantly higher during lactulose (4.28±0.23) than placebo (3.83±0.23) treatment (delta (Δ) 0.45 [95% confidence interval (CI) 0.10-0.80], 0.013). The defaecation days (days/week) was significantly higher during lactulose (3.77±0.17) than placebo (3.47±0.17) treatment (Δ0.30 [95% CI 0.04-0.56], 0.024). Faecal consistency using the Bristol Stool Scale (/defaecation) was significantly higher during lactulose (3.84±0.10) than placebo (3.68±0.10) treatment (Δ0.16 [95% CI 0.00-0.31], 0.044). Faecal volume (/week) was significantly higher during lactulose (21.73±3.07) than placebo (17.65±3.07) treatment (Δ4.08 [95% CI 0.57-7.60], 0.024). The number of in faeces (log colony forming units/g faeces) was significantly higher during lactulose (9.53±0.06) than placebo (9.16±0.06) treatment (Δ0.37 [95% CI 0.23-0.49], <0.0001). The percentage of in faeces was also significantly higher during lactulose (25.3±1.4) than placebo (18.2±1.4) treatment (Δ7.1 [95% CI 2.9-11.4], 0.0014). Finally, straining at defaecation (/defaecation) during lactulose (3.62±0.24) treatment was significantly lower than during placebo (3.97±0.24) treatment (Δ0.35 [95% CI -0.69 - -0.02], 0.037). No significant difference was observed between lactulose and placebo with regard to flatulence. Severe adverse effects did not occur. Thus, oral ingestion of 2 g/day lactulose had a prebiotic effect, increasing the number and percentage of bifidobacteria in faeces, softening the faeces, and increasing defaecation frequency, but without increasing flatulence.

摘要

60 名排便频率为每周 2-4 次的健康日本女性参与了这项随机、双盲交叉试验。参与者随机接受 2 克/天乳果糖治疗 2 周和安慰剂治疗 2 周,洗脱期为 3 周。有 8 名不符合条件的参与者被排除在外,因此分析了 52 名参与者的数据。主要结局是排便频率,次要结局是排便天数、粪便稠度、粪便体积以及粪便中的 数量和百分比。乳果糖治疗期间(4.28±0.23 次/周)排便频率明显高于安慰剂治疗期间(3.83±0.23 次/周)(差值(Δ)0.45 [95%置信区间(CI)0.10-0.80],0.013)。乳果糖治疗期间(3.77±0.17 天/周)排便天数明显高于安慰剂治疗期间(3.47±0.17 天/周)(差值 0.30 [95% CI 0.04-0.56],0.024)。使用布里斯托粪便量表评估的粪便稠度(/排便)在乳果糖治疗期间(3.84±0.10)明显高于安慰剂治疗期间(3.68±0.10)(差值 0.16 [95% CI 0.00-0.31],0.044)。乳果糖治疗期间(21.73±3.07)粪便体积明显高于安慰剂治疗期间(17.65±3.07)(差值 4.08 [95% CI 0.57-7.60],0.024)。粪便中 的数量(对数菌落形成单位/克粪便)在乳果糖治疗期间(9.53±0.06)明显高于安慰剂治疗期间(9.16±0.06)(差值 0.37 [95% CI 0.23-0.49],<0.0001)。粪便中 的百分比在乳果糖治疗期间(25.3±1.4)也明显高于安慰剂治疗期间(18.2±1.4)(差值 7.1 [95% CI 2.9-11.4],0.0014)。最后,乳果糖治疗期间(3.62±0.24)排便时用力程度明显低于安慰剂治疗期间(3.97±0.24)(差值 0.35 [95% CI -0.69 - -0.02],0.037)。乳果糖和安慰剂之间在腹胀方面没有观察到显著差异。没有发生严重不良反应。因此,口服 2 克/天乳果糖具有益生元作用,增加粪便中双歧杆菌的数量和百分比,使粪便变软,增加排便频率,但不增加腹胀。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验